OPTN · Optinose, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.51M | - | $20.44M | $20.49M | $14.88M | - | $19.82M | $19.45M | $11.85M | - |
| Cost of Revenue | $1.75M | - | $2.06M | $1.98M | $1.23M | - | $2.23M | $2.57M | $1.71M | - |
| Gross Profit | $16.76M | - | $18.37M | $18.51M | $13.65M | - | $17.60M | $16.88M | $10.14M | - |
| R&D | $760.0K | - | $949.0K | $928.0K | $1.21M | - | $1.28M | $951.0K | $1.78M | - |
| SG&A | $23.59M | - | $19.48M | $24.13M | $20.52M | - | $18.01M | $20.10M | $22.72M | - |
| Total Operating Expenses | $26.10M | - | $22.49M | $27.04M | $22.95M | - | $21.52M | $23.63M | $26.21M | - |
| D&A | $64.0K | - | $65.0K | $83.0K | $83.0K | - | $102.0K | $105.0K | $72.0K | - |
| Operating Income | ($7.59M) | - | ($2.05M) | ($6.55M) | ($8.07M) | - | ($1.69M) | ($4.17M) | ($14.37M) | - |
| Interest Expense | $4.97M | - | $5.29M | $4.95M | $4.97M | - | $4.94M | $4.82M | $4.67M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($22.42M) | - | $467.0K | ($7.58M) | ($14.07M) | - | ($9.29M) | $2.63M | ($18.85M) | - |
| EPS - Basic | ($1.92) | - | $0.00 | ($0.05) | ($0.12) | - | ($0.08) | $0.02 | ($0.17) | - |
| EPS - Diluted | ($1.92) | - | $0.00 | ($0.07) | ($0.12) | - | ($0.08) | $0.02 | ($0.17) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72.93M | $84.48M | $82.50M | $91.36M | $51.64M | $73.68M | $66.84M | $71.31M | $83.93M | $94.24M |
| Accounts Receivable | $23.14M | $26.39M | $29.77M | $20.82M | $14.23M | $19.93M | $21.37M | $22.13M | $16.98M | $33.93M |
| Inventory | $11.30M | $11.46M | $11.30M | $11.41M | $10.31M | $8.05M | $8.04M | $7.73M | $8.30M | $9.44M |
| Accounts Payable | $1.42M | $450.0K | $3.78M | $1.73M | $1.91M | $3.89M | $5.01M | $6.48M | $6.24M | $5.29M |
| Current Assets | $112.01M | $125.84M | $128.22M | $128.93M | $81.12M | $105.33M | $98.62M | $103.61M | $112.17M | $140.48M |
| Total Assets | $114.85M | $128.78M | $131.02M | $131.87M | $83.71M | $107.73M | $101.41M | $106.07M | $114.92M | $144.22M |
| Current Liabilities | $175.01M | $162.81M | $162.43M | $32.70M | $32.70M | $176.52M | $163.98M | $164.30M | $166.30M | $178.73M |
| Long-term Debt | - | - | - | $125.29M | $130.65M | - | - | - | - | $0 |
| Total Liabilities | $176.22M | $169.15M | $172.12M | $174.72M | $182.92M | $194.34M | $179.02M | $175.73M | $188.71M | $200.85M |
| Stockholders' Equity | ($61.37M) | ($40.36M) | ($41.10M) | ($42.85M) | ($99.22M) | ($86.61M) | ($77.61M) | ($69.66M) | ($73.78M) | ($56.62M) |
| Retained Earnings | ($764.33M) | ($741.92M) | ($741.56M) | ($742.02M) | ($734.44M) | ($720.38M) | ($710.41M) | ($701.11M) | ($703.74M) | ($684.89M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.55M) | - | - | - | ($22.02M) | - | - | - | ($10.48M) | - |
| Investing Cash Flow | $0 | - | - | - | ($22.0K) | - | - | - | $0 | - |
| Financing Cash Flow | $0 | - | - | - | $7.0K | - | - | - | $162.0K | - |
| CapEx | $0 | - | - | - | $22.0K | - | - | - | $0 | - |
| Free Cash Flow | ($11.55M) | - | - | - | ($22.05M) | - | - | - | ($10.48M) | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 90.5% | - | 89.9% | 90.3% | 91.7% | - | 88.8% | 86.8% | 85.6% | - |
| Operating margin | -41.0% | - | -10.0% | -32.0% | -54.3% | - | -8.5% | -21.4% | -121.3% | - |
| EBITDA margin | -40.7% | - | -9.7% | -31.6% | -53.7% | - | -8.0% | -20.9% | -120.7% | - |
| Net margin | -121.1% | - | 2.3% | -37.0% | -94.5% | - | -46.9% | 13.5% | -159.1% | - |
| Free cash flow margin | -62.4% | - | - | - | -148.2% | - | - | - | -88.5% | - |
| FCF / Net income | 0.52 | - | - | - | 1.57 | - | - | - | 0.56 | - |
| R&D / Revenue | 4.1% | - | 4.6% | 4.5% | 8.1% | - | 6.5% | 4.9% | 15.1% | - |
| SG&A / Revenue | 127.4% | - | 95.3% | 117.8% | 137.9% | - | 90.9% | 103.3% | 191.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.5% | - | 0.4% | -5.7% | -16.8% | - | -9.2% | 2.5% | -16.4% | - |
| Return on equity | 36.5% | - | -1.1% | 17.7% | 14.2% | - | 12.0% | -3.8% | 25.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.64 | 0.77 | 0.79 | 3.94 | 2.48 | 0.60 | 0.60 | 0.63 | 0.67 | 0.79 |
| Quick ratio | 0.58 | 0.70 | 0.72 | 3.59 | 2.17 | 0.55 | 0.55 | 0.58 | 0.62 | 0.73 |
| Cash ratio | 0.42 | 0.52 | 0.51 | 2.79 | 1.58 | 0.42 | 0.41 | 0.43 | 0.50 | 0.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | -2.92 | -1.32 | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | 0.95 | 1.56 | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.5x | - | -0.4x | -1.3x | -1.6x | - | -0.3x | -0.9x | -3.1x | - |
| Equity multiplier | -1.87 | -3.19 | -3.19 | -3.08 | -0.84 | -1.24 | -1.31 | -1.52 | -1.56 | -2.55 |
| Liabilities / Assets | 1.53 | 1.31 | 1.31 | 1.32 | 2.19 | 1.80 | 1.77 | 1.66 | 1.64 | 1.39 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.16 | 0.16 | 0.18 | - | 0.20 | 0.18 | 0.10 | - |
| Inventory turnover | 0.15 | - | 0.18 | 0.17 | 0.12 | - | 0.28 | 0.33 | 0.21 | - |
| Days sales outstanding | 456d | - | 532d | 371d | 349d | - | 394d | 415d | 523d | - |
| Days inventory outstanding | 2357d | - | 1998d | 2102d | 3058d | - | 1319d | 1098d | 1776d | - |
| Days payable outstanding | 296d | - | 668d | 319d | 567d | - | 821d | 920d | 1336d | - |
| Cash conversion cycle | 2517d | - | 1862d | 2153d | 2841d | - | 892d | 593d | 964d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 24.4% | - | 3.1% | 5.3% | 25.6% | - | -1.3% | -5.5% | -19.7% | - |
| Revenue CAGR (3y) | 7.8% | - | -2.2% | 3.7% | 7.6% | - | 8.7% | 23.7% | 18.8% | - |
| Revenue CAGR (5y) | 21.3% | - | 10.5% | 25.1% | 76.7% | - | 59.8% | 72.5% | 68.8% | - |
| Gross profit growth (YoY) | 22.8% | - | 4.4% | 9.6% | 34.6% | - | -0.4% | -8.4% | -20.4% | - |
| Operating income growth (YoY) | 6.0% | - | -21.1% | -57.0% | 43.8% | - | 84.3% | 72.8% | 32.8% | - |
| Net income growth (YoY) | -59.4% | - | - | - | 25.4% | - | 37.8% | - | 25.6% | - |
| EPS growth (YoY) | -1500.0% | - | - | - | 29.4% | - | 55.6% | - | 65.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 47.6% | - | - | - | -110.4% | - | - | - | 45.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 38.1% | 53.4% | 47.1% | 38.5% | -34.5% | -52.9% | -5.7% | -14.6% | -64.5% | -160.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$78.23M totalProduct$78.23M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing OptiNose against the 5 most active filers in the same SIC group.